Niagen BioScience
Smarter science. Better aging. Pioneering NAD+ research.
Instagram
Instagram
Facebook
Facebook
LinkedIn
LinkedIn
YouTube
YouTube
X
X
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
Niagen IV launches across Medi-Spa clinics on high-end cruise ships, expanding Niagen Plus’ footprint Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced OneSpaWorld (NASDAQ: OSW) as the newest Niagen Plus ™ provider, engaged to offer pharmaceutical grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships. Marking Niagen Bioscience’s first cruise ship clinic partnership, this collaboration brings Niagen IV to guests at sea. Niagen IV launches across Medi-Spa clinics on high-end cruise ships Rob Fried, CEO of Niagen Bioscience, commented, “OneSpaWorld opens a new premium channel at sea, strengthens our rapidly expanding Niagen Plus clinic footprint, and supports our strategy to scale Niagen IV and injections outside of the U.S.” This partnership extends Niagen Bioscience’s fast-growing clinical channel for Niagen Plus, with Niagen IV and injections
NAD for Health: Opportunities & Challenges
NAD for Health: Opportunities & Challenges
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an increase to the Company’s previously disclosed share repurchase program (the “Program”), raising the total authorization from $10 million to $20 million of the Company's outstanding common stock. Through March 17, 2026, the Company has repurchased approximately $2.6 million of its common stock under the Share Repurchase Program. Additional information regarding share repurchases will be reported in the Company’s periodic reports filed with the SEC. Rob Fried, CEO, Niagen Bioscience, stated, “The recent repurchase of our common stock and $10 million increase in our program reflect the conviction we have in our strategy and long-term value. We will continue to take advantage of the disconnect between NAGE’s market valuation and the underlying strength of our business
Niagen Bioscience to Present at the 38th Annual ROTH Conference
Niagen Bioscience to Present at the 38th Annual ROTH Conference
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
By supporting investigator-initiated research worldwide, the program has helped establish Niagen Bioscience as a foundational force in advancing NAD+ understanding across the industry Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support program in the world. Rob Fried, CEO, Niagen Bioscience, commented, “Reaching more than 300 MTAs reflects the growing scientific momentum behind our patented nicotinamide riboside (NR) ingredient, Niagen ® . This program has contributed to 45 published clinical studies, making Niagen the most extensively researched patented NAD-boosting ingredient in the world. Across clinical and
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
Launch expands Niagen® into the growing skincare category through a limited-release model designed to generate consumer insights and inform future innovation Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Niagen ® Skincare Innovation Lab , a new product innovation platform designed to translate the Company’s leadership in NAD+ science into category-defining skincare. Debuting under the platform is Niagen NanoCloud™ , a limited-release, dermatologist-tested topical skincare product powered by Niagen Bioscience’s flagship ingredient, Niagen ® (patented nicotinamide riboside, or NR), created to generate consumer insights and help shape future topical innovation within the Company’s core Tru Niagen ® portfolio. Niagen Bioscience Launches Niagen® Skincare Innovation Labs and Debuts Niagen NanoCloud™, the First Topical Product Powered by Patented Niagen® Rob
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net income increased 103% year-over-year to $17.4 million in 2025 Adjusted EBITDA increased 139% year-over-year to $20.4 million in 2025 Cash and cash equivalents totaled $64.8 million at December 31, 2025 compared to $44.7 million at December 31, 2024 Full year 2026 net sales outlook reflects between 10-15% growth, excluding the recently sold reference standards segment Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total net sales increased 16% to $33.8 million, with Tru Niagen® sales of $27.5 million, up 21% from the prior year quarter. Gross margin increased 160 basis points to 64.1%. Net income of $4.1 million compared to $7.2 million in the prior year quarter. Q4 2024 benefited from a $3.5 million reversal of
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction. The divestiture further streamlines Niagen Bioscience’s operations, advances the Company's strategy to exit non-core activities, and focuses resources on NAD+ science, intellectual property, and commercial growth within the longevity industry. Rob Fried, CEO of Niagen Bioscience, remarked, “This transaction reflects our disciplined focus on what we do best—advancing NAD+ science and delivering clinically proven, patented Niagen ® solutions across consumer and clinical channels. Selling Reference Standards to LGC is a meaningful step in simplifying our business and ensuring we are allocating capital and
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®
Patent strengthens Niagen Bioscience’s intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion and deterring infringers Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent No. 12,558,367 , which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous and injectable formulations. Rob Fried, CEO of Niagen Bioscience, commented, “This patent expands our intellectual property for our patented NR ingredient, Niagen ® , into IV and injectable delivery formats. With expected protection through 2044, it supports Niagen’s exclusivity in delivering a superior IV and injectable product with significantly faster delivery and improved comfort for patients across our expanding
Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting - PubMed
Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting - PubMed
This study directly compared commercially administered NAD<sup>+</sup> IV and NR IV, providing preliminary real-world evidence of infusion tolerability and short-term safety. Exploratory metabolic outcomes were variable and warrant further investigation. Additional studies are needed to evaluate dos …
How To Boost NAD Levels To Fight Inflammation, Improve Recovery, and Slow Aging | Dr. Charles Brenner
How To Boost NAD Levels To Fight Inflammation, Improve Recovery, and Slow Aging | Dr. Charles Brenner
Dr. Rhonda Patrick and Dr. Charles Brenner discuss NAD precursors, NR versus NMN, NAD IV drips, and what truly boosts NAD for recovery and longevity.
Going the Distance: US Olympic… - Pregnantish - Apple Podcasts
Podcast
·
Podcast
Going the Distance: US Olympic… - Pregnantish - Apple Podcasts
Podcast Episode · Pregnantish · 01/11/2026 · 40m
The divergent effects of nicotinamide riboside and high-intensity exercise training on skeletal muscle epigenetic aging
The divergent effects of nicotinamide riboside and high-intensity exercise training on skeletal muscle epigenetic aging
The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation: iScience
The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation: iScience
Nicotinamide adenine dinucleotide (NAD) augmentation therapy (NAD-AT) is increasingly explored in clinical trials across multiple indications, especially neurological diseases, yet its human pharmacokinetic profile remains incompletely defined. We report findings from a Phase I pharmacokinetic trial assessing systemic and cerebral responses to oral NAD precursors in healthy individuals (n=6) and persons with Parkinson's disease (n=6) receiving 1200 mg/day nicotinamide riboside or nicotinamide mononucleotide.
541: Can a Pill Help You Live … - The Genius Life - Apple Podcasts
Podcast
·
Podcast
541: Can a Pill Help You Live … - The Genius Life - Apple Podcasts
Podcast Episode · The Genius Life · 01/12/2026 · 1h 6m
5 Supplements Women over 50 Should Consider
5 Supplements Women over 50 Should Consider
Here are the top 5 supplements experts recommend for health and longevity for women over 50.
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today ...
541: Can a Pill Help You Live … - The Genius Life - Apple Podcasts
Podcast
·
Podcast
541: Can a Pill Help You Live … - The Genius Life - Apple Podcasts
Podcast Episode · The Genius Life · 01/12/2026 · 1h 6m
The Best Products from the Most Popular Wellness Brands of 2025 - Athletech News
The Best Products from the Most Popular Wellness Brands of 2025 - Athletech News
Tru Niagen and Barebells were among the most popular wellness brands online – see the full list and bestsellers to try.
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today ...
BlueMatrix
BlueMatrix
CRN Announces Board of Directors Election Results; Association Leadership in Place to Address 2026 Challenges and Opportunities for the Dietary Supplement and Functional Food Industry | Council for Responsible Nutrition
CRN Announces Board of Directors Election Results; Association Leadership in Place to Address 2026 Challenges and Opportunities for the Dietary Supplement and Functional Food Industry | Council for Responsible Nutrition
The Wild West World Of Supplements—What Consumers Should Know
The Wild West World Of Supplements—What Consumers Should Know
Exclusive | Buzzy NAD+ treatment boosts energy, better sleep and recovery | New York Post
Exclusive | Buzzy NAD+ treatment boosts energy, better sleep and recovery | New York Post
Long Covid Podcast- Cellular Recharge: Can N…
Podcast
·
Podcast
Long Covid Podcast- Cellular Recharge: Can N…
Exclusive: NAD+ supplement leader Tru Niagen enters the beauty supplement market, targeting the ‘much younger’ wellness consumer
Exclusive: NAD+ supplement leader Tru Niagen enters the beauty supplement market, targeting the ‘much younger’ wellness consumer
Healthcare Practitioner Webinar Series – Episode 30 - Exploring Niagen in Individuals with Long COVID Symptoms - Demio
Healthcare Practitioner Webinar Series – Episode 30 - Exploring Niagen in Individuals with Long COVID Symptoms - Demio
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial - eClinicalMedicine
Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial - eClinicalMedicine
Niagen Bioscience Announces $10 Million Share Repurchase Program
Niagen Bioscience Announces $10 Million Share Repurchase Program
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
NAD+ market analysis: From hype to reality check
NAD+ market analysis: From hype to reality check
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
niagenbioscience.com
niagenbioscience.com
truniagen.com
truniagen.com
Tru Niagen Instagram
Tru Niagen Instagram
Tru Niagen TikTok
Tru Niagen TikTok
Tru Niagen Facebook
Tru Niagen Facebook
Tru Niagen YouTube
Tru Niagen YouTube
Tru Niagen on X
Tru Niagen on X
niagenplus.com
niagenplus.com
Niagen Plus Instagram
Niagen Plus Instagram
Niagen Plus TikTok
Niagen Plus TikTok
Niagen Plus Facebook
Niagen Plus Facebook
Niagen Plus on X
Niagen Plus on X
View on mobile
